Our findings further suggest that genomic instability due to PI3K depletion should be considered an important side effect in anticancer therapies based on PI3K inhibitors, along with hyperinsulinemia and hyperglycemia (Nunnery & Mayer, 2019). The gene discussed is PIK3CD; the disease is Hyperinsulinemia.